Racial discrimination may exacerbate obesity risk in children

AbbVie has the option to obtain a co-exclusive licence for reproxalap’s development, manufacture and commercialisation in the US. Credit: Valeriya Zankovych / Shutterstock.com. Aldeyra Therapeutics

The FDA on Wednes­day said it’s look­ing to bet­ter un­der­stand the sci­en­tif­ic chal­lenges that are slow­ing the de­vel­op­ment of in­di­vid­u­al­ized cell and gene ther­a­pies. The

Development of autoimmune disease was more common in patients with surgical remission of Cushing’s disease than in those with surgically treated nonfunctioning pituitary adenomas (NFPAs),